RT Journal Article
T1 LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology.
A1 Garrido, Pilar
A1 Paz-Ares, Luis
A1 Majem, Margarita
A1 Morán, Teresa
A1 Trigo, José Manuel
A1 Bosch-Barrera, Joaquim
A1 Garcίa-Campelo, Rosario
A1 González-Larriba, José Luis
A1 Sánchez-Torres, José Miguel
A1 Isla, Dolores
A1 Viñolas, Núria
A1 Camps, Carlos
A1 Insa, Amelia
A1 Juan, Óscar
A1 Massuti, Bartomeu
A1 Paredes, Alfredo
A1 Artal, Ángel
A1 López-Brea, Marta
A1 Palacios, José
A1 Felip, Enriqueta
K1 BEAMing
K1 EGFR mutations
K1 liquid biopsy
K1 non-small cell lung carcinoma
AB The aim of LungBEAM was to determine the value of a novel epidermal growth factor receptor (EGFR) mutation test in blood based on BEAMing technology to predict disease progression in advanced non-small cell lung cancer (NSCLC) patients treated with first- or second-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Another goal was to monitor the dynamics of EGFR mutations, as well as to track EGFR exon 20 p.T790M (p.T790M) resistance during treatment, as critical indicators of therapeutic efficacy and patient survival. Stage IV NSCLC patients with locally confirmed EGFR-TKI sensitizing mutations (ex19del and/or L858R) in biopsy tissue who were candidates to receive first- or second-generation EGFR-TKI as first-line therapy were included. Plasma samples were obtained at baseline and every 4 weeks during treatment until a progression-free survival (PFS) event or until study completion (72-week follow-up). The mutant allele fraction (MAF) was determined for each identified mutation using BEAMing. A total of 68 of the 110 (61.8%) patients experienced a PFS event. Twenty-six patients (23.6%) presented with an emergent p.T790M mutation in plasma at some point during follow-up, preceding radiologic progression with a median of 76 (interquartile ratio: 54-111) days. Disease progression correlated with the appearance of p.T790M in plasma with a hazard ratio (HR) of 1.94 (95% confidence interval [CI], 1.48-2.54; p  Detection and quantification of EGFR mutations in circulating tumor DNA using the highly sensitive BEAMing method should greatly assist in optimizing treatment decisions for advanced NSCLC patients.
YR 2021
FD 2021-07-23
LK http://hdl.handle.net/10668/18236
UL http://hdl.handle.net/10668/18236
LA en
DS RISalud
RD Apr 5, 2025